Gyre Therapeutics (GYRE) Common Equity (2010 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Common Equity of $137.0 million for Q1 2026, up 31.33% year-over-year from $104.3 million in Q1 2025, and up 29.19% quarter-over-quarter from $106.0 million in Q4 2025.
Gyre Therapeutics (GYRE) Common Equity (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Common Equity for 17 consecutive years, with $137.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity rose 31.33% year-over-year to $137.0 million; the TTM figure through Mar 2026 stood at $137.0 million (up 31.33% YoY), while the FY2025 annual figure was $106.0 million, up 7.75% from the prior year.
- Common Equity climbed to $137.0 million in Q1 2026 per GYRE's latest filing, from $106.0 million in the prior quarter.
- Across five years, Common Equity topped out at $137.4 million in Q3 2025 and bottomed at $13.9 million in Q4 2023.
- Historically, Common Equity has averaged $85.6 million across 5 years, with a median of $88.8 million in 2024.
- Annual changes were most pronounced in 2023 — Common Equity plunged 80.68% — and 2024, when it surged 605.44%.
- Gyre Therapeutics' Common Equity stood at $72.2 million in 2022, then slumped by 80.68% to $13.9 million in 2023, then soared by 605.44% to $98.4 million in 2024, then rose by 7.75% to $106.0 million in 2025, then grew by 29.19% to $137.0 million in 2026.
- Business Quant data shows GYRE's Common Equity at $137.0 million in Q1 2026, $106.0 million in Q4 2025, and $137.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | 142.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 142.49 Mn |
| Mar 31, 2026 | 136.99 Mn |
| Dec 31, 2025 | 106.03 Mn |
| Sep 30, 2025 | 137.42 Mn |
| Jun 30, 2025 | 129.44 Mn |
| Mar 31, 2025 | 104.30 Mn |
| Dec 31, 2024 | 98.40 Mn |
| Sep 30, 2024 | 98.47 Mn |
| Jun 30, 2024 | 93.35 Mn |
| Mar 31, 2024 | 88.77 Mn |
| Dec 31, 2023 | 13.95 Mn |
| Sep 30, 2023 | 85.32 Mn |
| Jun 30, 2023 | 77.47 Mn |
| Mar 31, 2023 | 77.33 Mn |
| Dec 31, 2022 | 72.22 Mn |
| Sep 30, 2022 | 29.38 Mn |
| Jun 30, 2022 | 79.06 Mn |
| Mar 31, 2022 | 27.08 Mn |
| Dec 31, 2021 | 59.47 Mn |
| Sep 30, 2021 | 60.74 Mn |